EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Correction of neuroimmune disorders in a post-viral chronic fatigue syndrome model using recombinant interleukin-2

Tatiana A. Filatenkova, Sergey N. Shanin, Elena E. Fomicheva, Natalia B. Serebryanaya

Medical academic journal · 29.06.2026 · 26 (2) · 64-72

DOI: 10.17816/maj677939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical academic journal, online erschienen am 29.06.2026. Verfasst von Tatiana A. Filatenkova und 3 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chronic fatigue syndrome is a severe chronic condition that affects multiple body systems. The lack of accurate diagnostic tools makes it difficult to assess its prevalence and to select appropriate treatment strategies. During the COVID-19 pandemic, the number of patients with chronic fatigue symptoms increased sharply. There is substantial evidence that many infectious diseases, including influenza and enteroviruses, can trigger symptoms of this syndrome. Neurological manifestations in chronic fatigue syndrome include memory impairment, headaches, sleep disturbances, unexplained joint and muscle pain, and hypoactivation of the hypothalamic-pituitary-adrenal axis. AIM: To determine whether recombinant interleukin-2 can correct neuroinflammation and fatigue/tiredness in a rat model of chronic fatigue syndrome. METHODS: The study was conducted on 50 male Wistar rats. The disease was induced by a single intraperitoneal injection of Poly I:C at 3 mg/kg body weight. Half of the animals received recombinant IL-2 (30 mg/kg) on the first day after syndrome induction. On days 7 and 10 of the experiment, motor activity, emotional status, and the degree of physical fatigue were assessed. After tissue collection, plasma lactate concentration, hypothalamic expression of Il1β, Il10, Infα, 5Htt, Tlr3, as well as splenic lymphocyte cytotoxic and proliferative activity (as markers of immune system function), were determined. RESULTS: A single administration of recombinant IL-2 positively influenced motor activity and normalized emotional responses, reducing anxiety-like behavior, restored splenic lymphocyte cytotoxic and proliferative activity, and prevented the increase in expression of inflammation-related genes. The exception was the Tlr3 gene, whose expression did not decrease at any time point, although positive trends were observed after IL-2 injection. CONCLUSION: Administration of recombinant IL-2 did not eliminate muscle weakness but accelerated the normalization of physical activity and emotional status, reducing anxiety as early as day 7 of the experiment.

Zitieren

APA

Filatenkova, T. A., Shanin, S. N., Fomicheva, E. E., & Serebryanaya, N. B. (2026). Correction of neuroimmune disorders in a post-viral chronic fatigue syndrome model using recombinant interleukin-2. Medical academic journal, 26(2), 64-72. https://doi.org/10.17816/maj677939

Vancouver

Filatenkova TA, Shanin SN, Fomicheva EE, Serebryanaya NB. Correction of neuroimmune disorders in a post-viral chronic fatigue syndrome model using recombinant interleukin-2. Medical academic journal. 2026;26(2):64-72. doi:10.17816/maj677939

BibTeX
@article{Filatenkova2026,
  author = {Filatenkova, Tatiana A. and Shanin, Sergey N. and Fomicheva, Elena E. and Serebryanaya, Natalia B.},
  title = {Correction of neuroimmune disorders in a post-viral chronic fatigue syndrome model using recombinant interleukin-2},
  journal = {Medical academic journal},
  year = {2026},
  volume = {26},
  number = {2},
  pages = {64--72},
  doi = {10.17816/maj677939}
}
Kostenlos starten →